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pounds, in particular pun'ne or azidopurine containing com
pounds are taught. These sites provide for the site-speci?c
attachment of nucleotide photoa?inity compounds to anti
bodies, e.g., ATP- or GTP-analog photoa?inity compounds

by photochemical reaction. These nucleotide photoa?inity
compounds may additionally be attached to molecules hav
ing a desired therapeutic or diagnostic activity, and the
resultant conjugates used as diagnostics or therapeutics.
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NUCLEOTIDE OR NUCLEOSIDE
PHOTOAFFINITY COMPOUND MODIFIED

coupling the antigen-antibody reaction with suitable detec
tion techniques such as labeling with radioisotopes or with
detectable enzymes (RIA, EMIT, and ELISA). Antibodies

ANTIBODIES, METHODS FOR THEIR

are thus the foundation of immunodiagnostic tests for many

MANUFACTURE AND USE THEREOF AS
DLAGNOSTICS AND THERAPEUTICS

antigenic substances.
Another important application of antibodies involves their
use as therapeutics. The therapeutic administration of anti
bodies has recently been described for the treatment of

CROSS REFERENCE TO RELATED
APPLICATIONS

numerous disease conditions including cancer, and numer
ous infectious diseases.

This application relates to U.S. Ser. No. 08/138,109 ?led
on Oct. 20, 1993. This application is incorporated by refer
ence in is its entirety herein.

The therapeutic usage of antibodies has been the focus of
greater interest since the development of monoclonal anti

body/hybridoma technology by Kohler and Milstein (Proc.

FIELD OF THE INVENTION

Natl. Acad. Sci., USA, 772197 (1980)). Monoclonal anti
bodies, which are produced by hybridomas, are preferable to
polyclonal antibodies because of their greater antigenic
speci?city. Monoclonal antibodies have a lesser tendency

The present invention relates to the discovery of novel site
or sites on antibodies having high a?inity for nucleotide or

nucleoside photoa?inity compounds. The present invention
further relates to the use of these novel site or sites as a target

for photoaf?nity labeling using nucleotide or nucleoside
photoa?inity compounds and for the attachment of mol
ecules having a particular chemical or biological activity. In

20

hybridoma (mammalian) origin. Also, hybridoma cell lines

antibodies having high a?inity for purine or purine deriva

ity.

tend to be unstable and may alter the production of the
25

In an effort to obviate some of the problems associated

30

The present invention further relates to compositions,
invention still further relates to novel compositions, methods
and test kits which use the procedure of photoa?inity label

recombinant immunoglobulins and immunoglobulin frag
ments, and methods for their production.
To enhance or modify the properties of recombinant

ing with nucleotide a?inity probes, to attach molecules
having a desired chemical or biological activity to antibody

antibodies, it is further known to produce mutant or chimeric

molecules.
40

BACKGROUND OF THE INVENTION

Antibodies are speci?c immunoglobulin molecules pro
duced by vertebrate immune systems in response to chal

or to rid the system of foreign substances is at least partially
understood. An important part of this process is the manu
facture of antibodies which bind speci?cally to a particular

foreign antigenic substance. The binding speci?city of such
polypeptides to a particular antigen is highly re?ned, and the
multitude of speci?cities capable of being generated by an

45

prise antigen-binding sites from a non-human species (typi
cally murine) but wherein the remainder of the immunoglo
bulin is of human origin are known in the art, and have been

reported to have signi?cant potential as therapeutics because

50

of their reduced antigenicity. It is further known to produce
recombinant antibodies of single chain form, which com
pletely lack constant domain sequences but which bind

antigen. (See, Bird et al., Science, 242, 423-426 (1988)).
In order to increase the ef?cacy of antibody molecules as
diagnostic or therapeutic agents, it is conventional to
covalently bind or complex desired molecules thereto, in
particular effector or reporter molecules. Effector molecules

variability. Thousands of antigens are capable of eliciting
antibody responses, each almost exclusively directed to the

essentially comprise molecules having a desired activity,

particular antigen which elicited it.

e.g., cytotoxic activity. By contrast, a reporter molecule is

Immunoglobulins include both antibodies, as above

de?ned as any moiety which may be detected using an assay.
Examples of effector molecules which have been attached to
60

antibodies include by way of example, toxins, anti-tumor
agents, therapeutic enzymes, radionuclides, antiviral agents,

chelating agents, cytokines, growth factors, and polynucle
otides. Examples of reporter molecules which have been
conjugated to antibodies include, by way of example,

the humoral arm of the immune defense system. Because of

their antigen speci?city, antibodies comprise numerous

diagnostic and therapeutic applications. For example, they

antibodies, e.g., which comprise sequences from several
different mammalian species or bispeci?c antibodies which
comprise antigenic binding sequences from two diiferent
antibodies. For example, humanized antibodies which com

individual vertebrate is remarkable in its complexity and

described, and analogous protein substances which lack
antigen speci?city. The latter are produced at low levels by
the lymph system and in increased levels by myelomas.
Antibodies are produced by B lymphocytes and represent

binding speci?city, researchers have used recombinant tech
niques to produce immunoglobulins which are analogous or
modi?ed in comparison to antibodies normally found in
vertebrate systems. For example, U.S. Pat. No. 4,816,397
issued on Mar. 28, 1989 to Boss et al. and U.S. Pat. No.
4,816,567 issued on Mar. 28, 1989 to Cabilly et al. disclose

nucleotide photoaf?nity labeled antibodies. The present

typically foreign substances. The sequence of events which
permits an organism to overcome invasion by foreign cells

antibody produced or stop secreting the antibody altogether.
with polyclonal and monoclonal antibodies, and further to
obtain a reproducible supply of antibodies having a de?ned

methods, and test kits which contain or use the subject

lenge by foreign proteins, glycoproteins, cells, or other

corresponding antigen. However, monoclonal antibodies
still su?er from some disadvantages, e.g., they tend to be
contaminated with other proteins and cellular materials of

particular, the present invention concerns a site or sites on

tive containing photoaf?nity compounds, e.g., ATP- or GTP
analog photoa?inity compounds and the use of these sites as
targets for purine or purine derivative photoaf?nity com
pounds or other heterocyclic base containing compounds
which have a?inity for these sites and for the attachment of
molecules having a particular chemical or biological activ

than polyclonal antibodies to non-speci?cally bind to non
targeted moieties, e.g., cells which do not express the

65

enzymes, radiolabels, ?uorescent labels, phosphorescent I

can be used as speci?c imrnunoprecipitating agents to detect

molecules, chemiluminescent molecules, chromophores,

the presence of an antigen which they speci?cally bind by

luminescent molecules, and colored particles.

5,596,081
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While it is desirable to attach molecules to antibodies in

with hapten-based af?nity labels. Essentially, hapten-based

order to impart a desired activity to the antibody or provide
for the detection thereof, the attachment of desired mol
ecules to antibodies is not always possible to carry out
conveniently, or effectively, because such attachment may

affinity labels react with amino acids in the antigen binding

site, thereby destroying this site and blocking speci?c anti
gen reaction. However, this is disadvantageous since it

results in loss of antigen binding by the antibody conjugate.

result in loss of antibody activity. In particular, current
methods for generating radiolabeled antibodies for diagnos

Thus, based on the foregoing, it is clear that there still
exists a signi?cant need in the art for improved methods of
attaching molecules to antibodies, in particular effector or
reporter molecules, which are site-speci?c and which more

tic and therapeutic use su?er from such limitations. For

example, the ratio of target-speci?c versus non-speci?c
uptake of radiolabeled antibodies used in tumor imaging is
often low, resulting in unclear images or missing tumor sites.
Moreover, the low therapeutic index of radiolabeled anti

over result in antibody conjugates having substantially unal
tered structure and biological activity, most especially anti

gen binding activity.

bodies limits the use of high radiation doses in radiation

Molecules containing azido groups have been shown to

therapy.

form covalent bonds to proteins through reactive nitrene

The underlying reason for such problems is largely
because the labeling chemistry for introduction of the radio
label results in the partial denaturation of the antibody
structure, which in turn causes the antibodies to aggregate in

vivo or in vitro. Aggregated and damaged immunoglobulins
are recognized by scavenger cells in the body, such as
macrophages and Kupffer cells in the liver and lung.
Another problem is that most coupling strategies result in
non site-speci?c attachment of the molecule to the antibody
molecule, in particular, attachment may occur at antibody
residues which are essential for antigen binding or other
antibody functions. For instance, a known site of attachment
of desired molecules to antibody molecules comprise thiol
groups, since thiol groups occur naturally in proteins as
cysteine residues. However, such residues are relatively

intermediates, generated by low intensity ultraviolet light.
Potter & Haley, Meth. in Enzymol, 91, 613-633 (1983). In
particular, 2- and 8- azido analogues of purine nucleotides
have been used as site directed photoprobes to identify
nucleotide binding proteins in crude cell extracts. Owens &
20
Haley, J. Biol. Chem., 259:14843-14848 (1987); Atherton et

al., Biol. of Reproduction, 32, 155-171 (1985). The 2- and
8-azido nucleotides have also been used to map nucleotide
25

binding domains of puri?ed proteins. Khatoon et al., Ann. of
Neurology, 26, 210-219 (1989); King et al., J. Biol. Chem,
269, 10210—10218 (1989); and Dholakia et al., J. Biol.

Chem, 264, 20638—20642 (1989).
Photoa?inity probes have been used to determine speci?c
nucleotide binding sites on a biologically active recombinant

peptide molecule. Campbell et al., PNAS, 87, 1243-1246
uncommon, are often inside the molecule and are frequently 30 (1990). The probes have also been used to study enzyme

involved in forming disul?de bridges within or between
protein molecules. Thus, there is a danger that if a naturally
occurring cysteine residue is used as a site of attachment, it
will interfere with the normal folding and stabilization of the

antibody protein.

kinetics of puri?ed proteins, Kim et al., J. Biol. Chem., 265,
3636—3641 (1990).
Recently, ATP or GTP analog photoa?inity labeled probes
35

In an e?’ort to obviate such problems, alternative strate

gies have been developed which provide for site-selective

disease in a mammal. U.S. Ser. No. 08/138,109 now U.S.

attachment of a desired molecules to antibodies, without loss

of antigen-binding activity. For example, it is known to
produce recombinant antibodies comprising cysteine resi

Pat. No. 5,445,937 ?led on Oct. 20, 1993 by Haley et a1.
40

particular nucleotide binding proteins to aid in the diagnosis
of cancer in a mammal and in the diagnosis of leukemia in
a mammal. (Id.)
However, while it had been previously known to use

facilitate the site-speci?c attachment of desired molecules

without loss of antigen binding properties. (See, U.S. Pat.
No. 5,219,996 issued on Jun. 15, 1993 to Bodmer et al.)
However, this is not always possible or convenient since it

obviously requires the possession of a recombinant DNA
It has further been proposed to derivatize immunoglobu

50

which purportedly do not result in alteration of the antibody

combining site. Antibody conjugates produced according to

55

ity, speci?city and sensitivity (U.S. Pat. No. 5,196,066
Site-speci?c attachment of effector or reporter molecules,
60

carbohydrate residue in the Fc region has also been dis
closed in the literature. (See, e.g., O’Shannessy et al., J.
Immun. Meth., 99, 153-161 (1987)). This approach has been

OBJECTS AND SUMMARY OF THE
INVENTION

It is, therefore, an object of this invention to identify
nucleotide or nucleoside a?‘inity sites on antibodies which

reported to produce diagnostically and therapeutically prom~
ising antibodies which are currently in clinical evaluation.
Another known method of site-speci?c attachment of
molecules to antibodies comprises the reaction of antibodies

ously known that antibody molecules comprise nucleotide
photoa?inity sites, and in particular, sites having high a?in
ity for purine, azidopurine and other similar heterocyclic
bases, which may be e?iciently photolabeled using appro

priate photoa?inity probes.

issued on Mar. 2, 1993 to Bieniarz et al.).

wherein the reporter or effector molecule is conjugated to a

nucleotide photoaf?nity probes, and speci?cally purine con
taining photoaf?nity analogs (GTP- and ATP-analogs), to
map nucleotide binding domains of puri?ed proteins and to
identify speci?c nucleotide binding sites on recombinant
peptide molecules, the use of nucleotide photoaf?nity probes
to label antibodies has not been previously reported in the
literature. This is essentially because it had not been previ

lins by selectively introducing sulfhydryl groups in the Fc
region of an immunoglobulin, using reaction conditions
this methodology are disclosed to exhibit improved longev

Additionally, ATP or GTP analog photoa?inity-labeling
reagents have been disclosed for use in the detection of

dues introduced into their surface structure to provide a thiol
group which is available for covalent binding to an elfector
or reporter molecule. This method has been reported to

encoding the particular antibody.

have been used to detect a glutamine synthetase nucleotide

binding protein having an apparent molecular weight of
about 42,000 proteins to aid in the diagnosis of Alzheimer’s

provides for the site speci?c photoinsertion of desired mol
65

ecules to antibodies. It is further a speci?c object of the
invention to characterize the effects of these af?nity sites on

antibody function.

5,596,081
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It is a more speci?c object of this invention to identify a

antibody, in particular a labeled purine or purine derivative

site or sites on antibodies having high a?inity for purines,
azido-purines and other similar heterocyclic organic com

containing compound labeled antibody, and more particu
larly a labeled ATP- or GTP-analog photoa?inity compound

pounds, in particular ATP- or GTP-analog photoa?inity

antibody.

compounds.

It is another object of the invention to provide improved

It is another speci?c object of the invention to provide

immunotherapeutics, wherein such immunotherapeutics

methods for coupling desired molecules, e.g., effector or
reporter molecules to an antibody by site-speci?c attachment

comprise an antibody conjugated or complexed to molecules
having therapeutic or cytotoxic activity, wherein the
improvement comprises using as the immunoconjugate an

of the molecules to nucleotide a?inity site or sites contained
on the antibody molecule or by attachment of the molecules IO antibody which comprises one or more therapeutic or cyto
toxic molecules site-speci?cally attached to the antibody via
to a nucleotide photoa?inity compound which has been
a nucleotide or nucleoside affinity site on the antibody. In the
photoinserted at said nucleotide a?inity site.

preferred embodiment, the a?inity site will have high af?nity
for purine derivatives, in particular ATP- or GTP-analog
photoaf?nity compounds. The present invention further pro

It is a more speci?c object of the invention to provide

methods for site-speci?cally photoaf?nity coupling a purine,
azidopurine or similar heterocyclic base containing com
pound, in particular an ATP- GTP-analog photoaf?nity com

vides methods of using said immunotherapeutics to treat
various disease conditions, and as imaging agents.
It is another object of the invention to provide test kits for

pound, which compound is attached to one or more mol
ecules having a desired activity, to a site or sites contained

detection of antigens comprising diagnostically e?‘ective

on the antibody molecule having high af?nity for purine,
azidopurine or other similar heterocyclic bases, or to pref
erably an ATP- or GTP-analog photoafiinity compound,

amounts of one or more of the following: antibodies, nucle

otide photoaf?nity probe, preferably an ATP- or GTP-analog

photoaf?nity compound, reporter, any substrate(s) necessary

which as been photoinserted onto said site or sites.

for the detection of the particular reporter, and diagnostic
carriers, and wherein the various moieties may be separate

It is another object of the invention to provide antibodies
conjugated to desired molecules, in particular, effector or
reporter molecules wherein such molecules are site-speci?

25

cally attached to the antibody via a nucleotide a?inity site,
or to a nucleotide photoaf?nity analog attached to said site,
It is a more speci?c object of the invention to provide

from one another or may be in various forms of attachment.
It is a more speci?c object of the invention to provide test

kits for detection of antigens comprising diagnostically
eil‘ective amounts of one or more of the following: antibod

ies, a purine, azidopurine and/or a similar heterocyclic base
containing photoa?inity probe, reporter, any substrates nec

antibodies conjugated to desired molecules, in particular,
reporter or eifector moieties wherein such ligands are

essary for the detection of the reporter and diagnostic
carriers, wherein the various moieties may be separate or
purine, azidopurine and other similar heterocyclic bases, in
may be in various forms of attachment.
particular ATP- or GTP-analog photoaf?nity compounds, or
It is yet another speci?c object of the invention to attach
to a nucleotide photoa?inity compound attached to said site.
heavy
metals to antibodies which may or may not be
It is another object of the invention to provide a method 35 radioactive, in particular, triphosphate chelated heavy metals

attached to the antibody at a site having high a?inity for

for photoa?inity labeling of antibodies by the attachment of

such as 111In3+ by reacting said chelated heavy metals with
nucleotide photoaf?nity compounds before or after such

nucleotide photoaf?nity probes to a nucleotide a?inity site or
sites contained on the immunoglobulin molecule.
It is a more speci?c object of the invention to provide a

nucleotide photoa?inity compounds are attached to a nucle
otide a?inity site or sites contained in an antibody molecule.

method for photoaf?nity labeling of antibodies by the attach

Other suitable heavy metals for photoattachment include,

ment of a labeled purine, azidopurine or other similar

e.g., mercury and iron. In the preferred embodiment, the

heterocyclic base containing photoa?inity probe, and in

nucleotide photoa?inity compound will comprise a purine,
azidopurine and/or a similar heterocyclic base containing

particular an ATP- or GTP-analog photoa?inity labeled
compound to a site or sites on the antibody having high

compound, and most preferably will comprise ATP- or

af?nity of purine, azidopurine and/or similar heterocyclic

GTP-analog photoa?inity compounds.

bases, and in particular ATP- or GTP-analog photoa?inity

It is yet another speci?c object of the invention to provide

compounds.

a novel method of attaching nucleic acids to antibodies, e.g.,
antisense nucleic acids, DNA, RNA or mixtures thereof,

It is another object of the invention to provide photoaf

?nity labeled antibodies and compositions containing,

comprising attaching said nucleic acids to the antibody
molecule using a nucleotide a?inity compound, preferably a
purine, azidopurine or similar heterocyclic base containing

wherein such antibodies have been coupled to a nucleotide

photoa?inity probe via a nucleotide a?inity site contained on
the antibody molecule.
It is a more speci?c object of the invention to provide
photoa?inity labeled antibodies and compositions contain
ing, wherein such antibodies have been coupled to a labeled
purine, azidopurine and/or similar heterocyclic base con
taining photoa?inity probe, in particular a labeled ATP- or

nucleotide a?inity compound, more particularly an ATP- or
55

It is a more speci?c object of the invention to attach
desired molecules, e. g., reporter or eifector molecules which

GTP-analog photoa?inity compound, at a site or sites on the

antibodies having high a?inity for purine, azidopurine and/

60

or heterocyclic bases.

amino groups, to an antibody by reacting same with a

methods of immunodetection of an antigen, wherein such
methods include the detection and/or quanti?cation of anti

nucleotide or nucleoside photoa?inity compound labeled

contain one or more reactive amino groups, or which have
been attached to a spacer comprising one or more reactive

nucleotide a?inity compound having a reactive cis-hydroyl
group containing ribose moiety, which cis-hydroyl group

It is another object of the invention to provide improved

gen-antibody complexes using a labeled antibody wherein
the improvement comprises using as the labeled antibody a

GTP-analog photoaf?nity compound which comprises a
highly negatively charged phosphate (tri or tetraphosphate)
having high affinity for positively charged polylysine.

may be converted to a dialdehyde under gentle conditions,
65

and wherein such attachment may be effected before or after

the nucleotide ailinity probe is attached to an antibody via
nucleotide a?inity site or sites contained on the antibody.

5,596,081
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BRIEF DESCRIPTION OF THE FIGURES

which provide for the selective site-speci?c attachment of
photoa?inity compounds thereto. In particular, it has been

FIG. 1 is a graph which compares the photoincorporation

discovered that antibodies comprise one or more sites hav

of [Y3ZPJ-8-N3ATP into the heavy and light chains of the

ing high a?inity for purines, azido-purines and other similar

SIC5 monoclonal antibody wherein the extent of photoin

heterocyclic organic compounds, and speci?cally ATP- or

corporation is quanti?ed by liquid scintillation counting.

GTP-analogs. However, the present inventors do not wish to
be limited to purine or azidopurine binding sites, since,

The results show that the radioactive probe covalently
attached to both heavy and light chains.
FIG. 2 is a graph which compares the photoincorporation

given the teachings in this application, other photoaf?nity
binding sites may further be identified, e.g., by reaction of
antibodies with non-purine containing photoa?inity com—
pounds, e.g., pyrimidine derivatives such as photoactive

of [f2P]-8-N3ATP into the heavy and light chain sof the
SIC5 monoclonal antibody in the presence of increasing
quantities of ATP wherein photoincorporation is quanti?ed
by liquid scintillation counting. The results indicate that

analogs of dUTP, including 5-azido-2'-deoxyuridine

5'-triphosphate (5-N3dUTP).
The purine or azidopurine nucleotide a?inity site will

50% inhibition occurs at about 350 pM.
FIG. 3 is a bar graph which compares the percent inhi

hereinafter be referred to as the “purine ring binding” or
simply the “PRB” domain or site.
The PRB site on antibody molecules was discovered after
it was found by the present inventors that photoaf?nity

bition of photoincorporation of [yazP]-8-N3ATP into the
SIC5 monoclonal antibody by oligonucleotides of diiferent
lengths, i.e., a 24-mer, a 30-mer, a 33-mer and a 58-mer,

wherein photoincorporation is again determined by liquid
scintillation counting. The bar graph shows that there is
much greater inhibition with larger oligonucleotides.

20

been discovered that antibodies comprise one or more PRB

sites which exhibit such a high a?inity for purines and

from 0 to 10 M) to inhibit binding of the same amount of 25

[f2P]-8-N3ATP labeled 3H1 monoclonal antibody to the
corresponding idiotypic antibody, and wherein the SD10

photoattachment.

Photoincorporation is again quanti?ed by liquid scintillation
30

clonal antibody inhibits binding of the labeled 3Hl antibody.

DI-IL4 human lymphoma tumor cells.

azidopurine photoa?inity analogs, that reaction of antibodies
with purine and azidopurine photoa?inity analogs under
mild, physiological conditions, and more particularly after
only a single 2—5 minute photolysis results in nearly 100%

antibody is used as a non-speci?c cold (unlabeled) inhibitor.

FIG. 5 is a bar graph which compares the ability of
different amounts of unlabeled SD10 monoclonal antibody
(5.0, 1.0, 0.5 pg) to inhibit binding of the same amount of
[ynPl-ii-NsATP labeled 5D 10 monoclonal antibody to live

ments by a photoactivated chemical reaction which occurs

under mild, physiological conditions. Speci?cally, it has

FIG. 4 is a graph of the results of a solid phase binding
assay [ELISA] which compares the ability of different
amounts of unlabeled 3H1 monoclonal antibody (ranging

counting. The results show that cold (unlabeled) 3H1 mono

compounds, in particular purine or azidopurine photoa?inity
compounds readily attach to antibodies and antibody frag

This is in contrast to the harsh and potentially damaging
conditions which are generally required to facilitate the
effective covalent attachment of desired molecules to anti

bodies. Thus, the present invention provides an improved
35

method for the attachment of desired molecules to antibod
ies, since it utilizes reaction conditions which are more

compatible with the preservation of labile biological mol
ecules and living cells.
However, it should be emphasized that while the condi
tions which facilitate the attachment of nucleotide photoaf
?nity compounds to antibodies are inherently gentle, this, in

.

FIG. 6 is a photograph of the isoelectric focussing pattern
of unlabeled and ['fzP]-8-N3ATP labeled SIC5 monoclonal

antibody, wherein the SIC5 antibody is photolabeled using
increasing concentrations of [YSZP]-S-N3ATP. The isoelec
tric focussing standards are Azcytochrome C(pI 9.6),
Bzequine myoglobin (pI 7.0), C=bovine carbonic anhydrase
(pI 6.0), D=phycocyanin (pI 4.65) (lane 10). The unlabeled
SIC5 antibody is in lane 1. The [YBZP]-8-N3ATP labelled

itself, did not ensure a successful outcome. Foremost, prior

to the invention, it could not have been predicted with any

degree of certainty that this photoa?inity reaction would
occur under any conditions, because it was not known that

antibodies comprise site or sites having affinity for photo
a?inity compounds, in particular nucleotide and nucleoside
photoaf?nity compounds, and more particularly sites having
high a?inity for purine, azidopurine or similar heterocyclic
base containing photoaf?nity compounds. Moreover, even

SIC5 antibody are as follows: 3.25 M (lane 9), 6.25 |J1VI

(lane 8), 12.5 pm (lane 7), 25 pM (lane 6), 50 1.1M (lane 5),
100 pM (lane 4), 200 pM (lane 3), 400 pM (lane 2).

FIG. 7 is a photograph of an autoradiograph made from an
SDS-PAGE on which diiferent antibodies which had been 50 assuming that the existence such sites had been known, it
photolabeled with [Y3ZP]-8~N3ATP were separated. In par
could not have been predicted that reaction with such sites

ticular, autoradiograph shows separation of a murine mono

with compatible photoa?‘inity compounds would not have
adversely a?°ected antibody activity, most especially the

clonal IgGl antibody, SD10 monoclonal antibody (lane 1),
murine myeloma IgGl (lane 2), murine myeloma IgA (lane

3)_, goat Ig (lane 4), goat (Fab)2 fragments (lane 5), human
myeloma IgGlK (lane 6), human myeloma IgGl (lane 7),

55

ability of the antibody to bind antigen. For example, it was
entirely possible that the nucleotide or nucleoside photoaf
?nity compounds could have inserted in the antibody mol

human myeloma IgM (lane 8), murine monoclonal IgM
{lane 9) and murine monoclonal IgG2b, SIC5 (lane 10)
which had photolyzed in the presence of 200 pM [7”P1-8
N3ATP and were separated by 8—16% gradient SDS-PAGE,

was lost or substantially impaired. Alternatively, it was
60 possible that the insertion of the nucleotide or nucleoside

stained with Coomassive Blue, dried and autoradiographed.

photoa?inity compounds into antibody molecules could

DETAILED DESCRIPTION OF THE
PREFERRED EMBODIMENTS OF THE
INVENTION

have induced conformational changes in the antibody mol
ecule causing substantial reduction or loss of other antibody
functions. However, quite surprisingly it has been found that

The present invention provides the discovery that some, if
not all, antibodies contain one or more photoaf?nity sites

ecule at a site or sites within or sufficiently proximate to the

antigen combining site, such that antigen binding activity

65

nucleotide photoaf?nity analogs readily attach to antibodies,
in a site-speci?c manner, under conditions which do not

result in substantial loss of antigen binding activity.

5,596,081
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antibody. The invention further provides general methods

invention will preferably comprise adenine analogs,
although guanine analogs can be substituted therefor. For
example, purine binding sites may be effectively labeled by
the following, and their 5'-mono-, di- and triphosphates:

for studying the function of these nucleotide and nucleoside

oligomers of a single azidoadenylyl species, such as, for

Thus, the invention in general provides a novel means for

site-speci?cally photoattaching desired molecules to anti
bodies nucleotide or nucleoside a?inity sites contained in the

affinity sites, by binding different nucleotide and nucleoside
photoa?inity compounds to these sites and evaluating their

example: 2-azido or 2-azidoadenylyl(2'—5‘)2-azidoadeny-'
lyl(2'-5‘)2-azidoadenosine; 2-azido or 8-azidoadadenosine;

effects on antibody functions, e.g., e?’ector functions.
As discussed in the Background of the Invention, methods

8-azidoadenylyl(2'—5')-8-azidoadenylyl(2‘—5‘)8-azidoad
enosine; 8-azidoadenylyl(2'—5')- 8-azidoadenylyl(2'—5')8
azidoadenylyl-(2'—5')8-azidoadenosine; 2,8-diazidoadeny

for photoinsertion of nucleotide photoa?inity compounds,
and speci?cally purine and purine analog photoa?inity com
pounds in proteins having speci?c nucleotide binding sites

lyl(2'—5‘)2,8-diazidoadenylyl(2'—5')2,8-diazido-adenosine;
2,8-diazidoadenylyl(2'—5‘)2,8-diazidoadenylyl(2‘—5')2,8-di

have been reported in the literature. The subject invention

azidoadenylyl(2‘—5')2,8-diazidoadenosine; also oligomers of

embraces any set of reaction conditions which provides for

AMP and a single azidoadenylyl species, such as, for

the effective photoinsertion of a nucleotide or nucleoside

example: 2-azidoadenylyl(2'—5')2-(2'—5‘)adenosine; adeny

photoa?inity compound, preferably a purine, azidopurine or

lyl(2'—5')8-azido-adenylyl(2'—5‘)8-azidoadenosine; also oli

similar heterocyclic base containing photoaf?nity analog,

gomers containing more than one azidoadenylyl species,

and most preferably an ATP- or GTP-analog photoa?inity
compound, into an antibody molecule, which does not result

in substantial loss of antigen binding.
Suitable methods for attaching nucleotide photoa?inity

such as, for example: 2-azidoadenylyl(2‘-5‘)8-azidoadeny

lyl(2'—5')2-azidoadenosine; also oligomers resulting from
20

one such monomer incorporated into the oligomer is an

analogs to proteins are described, e.g., in Potter & Haley,
Meth. in EnzymoL, 91:613-633, (1983); Owens & Haley, J.
Biol. Chem., 259: 14843-148 48, (1987); Atherton et al, Biol.

of Reprod, 32:155-171, (1985); Khatoon et al, Ann. of
Neurology, 26:210-219, (1989); King et al, J. Biol. Chem,

azido-AMP species.
25

269210210-10218, (1989); Dholakia et al, J. Biol. Chem,
264:2063 8-20642, (1989); Campbell et al, Proc. Natl. Acad.
Sci., 87:1243-1246, (1990); and Kim et al, J. Biol. Chem,
265:3636-3641, (1990), which references are incorporated
by reference in their entirety herein.

Alternatively, guanine moieties can be de?ned in each of

the exemplary compounds in place of the respective adenine
moieties. Therefore, certain most preferred compounds of
the present invention are synthesized from azidoguanosine

Any antibody or antibody containing composition which
35

such antibodies, and the number and affinity of nucleotide or

nucleoside binding sites present on the particular antibodies.
Suitable conditions can readily be determined by the skilled
artisan by reference to the above-cited publications relating
to nucleotide photoa?inity labeling of proteins, and the

examples therein.

(2'—5‘)oligomer containing both guanylyl and azidoguanylyl
Furthermore, photoaf?nity compounds of the present
invention may also include, for example, pyrimidine deriva
tives. For instance, photoactive analogs of dUTP, such as

S-azido-2‘-deoxyuridine 5'-triphosphate (5-N3dUTP), may
be synthesized from dUMP and provide a pathway for the
synthesis of other useful S-substituted uridine nucleotides.
45

50

nucleic acids which remain stable to extremes of pH and
which remain effective photolabeling reagents in the pres
ence of reducing agents. Moreover, since the synthesis of
5-N3dUTP employs mild conditions, it is also possible to

synthesize homopolymers of 5-N3dUTP to provide single

The invention further embraces the use of any nucleotide

photoinserts into one or more nucleotide a?inity sites of a

substantial retention of antigen binding activity. Moreover,

The S-diazouridine nucleotides may, for example, serve as
active-site-directed photoa?inity probes or as substrates for

polymerizing enzymes to generate additional photoactive

or nucleoside photoa?inity compounds which effectively

selected antibody under conditions which provide for the

5'-triphosphates or combinations thereof, or from azidogua
nosine 5‘-triphosphates and ATP. The latter provides a
moieties.

factors including the concentration of antibodies in the

particular composition, the isotype and/or species origin of

In addition photoaflinity compounds of the invention may
also include photoactive coenzyme analogs of NAD“, exem
pli?ed by nicotinamide 2-azidoadenosine dinucleotide
(2-azido-NAD‘“), or analogs of NADH, exempli?ed by
nicotinamide 2-hydrazidoadenosine dinucleotide (2-azido

NADH).

effectively binds nucleotide or nucleoside photoa?inity com
pounds is within the scope of the present invention. This

includes by way of example, polyclonal and monoclonal
antibodies, recombinant antibodies, chimeric antibodies,
bispeci?c antibodies, single chain antibodies, antibodies
from di?ierent species (e.g., mouse, goat, rabbit, human, rat,
bovine, etc.), anti-idiotypic antibodies, antibodies of differ
ent isotype (IgG, IgM,1gE, lgA, etc.), as well as fragments
and derivatives thereof. (e.g., (Fab)2 fragments.)
Optimal reaction conditions will vary dependent upon

any combination of the monomers AMP, 2-azido-AMP,
8-azido-AMP and/or 2,8-diazido-AMP, provided that at least

55

stranded photoactive DNA of de?ned length. Using
5-N3dUTP one can similarly produce photoactive RNA.
Generalized methods for the synthesis of aryl azides
include nucleophilic displacement of a bromine, chlorine or

if the antibody is to be used as a therapeutic agent, such

nitro group by an azide ion or the addition of sodium azide

conditions should preferably preserve other antibody func
tions, e. g., effector functions, comprised in the Fc portion of

to an acidic solution containing a diazotized primary aro

the antibody molecule (e.g., complement activation).
The particular nucleotide or nucleoside photoa?inity
compound may be directly reacted with an antibody, or it

matic amine.
60

To date the most widely used 8-azidopurine is probably
8N3cAMP. One of the advantages of 8N3cAMP is that in
mammalian systems there are only two types of proteins that

may ?rst be attached to another compound, e.g., a molecule
are known to bind cAMP with high a?inity, the cAMP
having a desired effector function or a reporter molecule,
phosphodiesterases and the regulatory subunits of the
e.g., a radioactive label.
65 cAMP-dependent protein kinases. The photoprobes [32F]

Many nucleotide photoaf?nity probes may be synthesized

8N3cAMP and [32P]8N3ATP have been employed to study,

and used successfully. The photoa?inity compounds of the

for example, the mechanisms of action of cAMP-dependent

5,596,081
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protein kinase. Photoactive analogs of GTP, e.g., [32F]
8N3GTP, have been developed to study, for example, tubulin
polymerization, while photoactive analogs of UTP, e.g.,
[32P]5N3dUTP have been generated to study, for example,
the binding site of DNA binding proteins.

tion). Solution hybridization is preferred in the present
method. Another method of interest is the sandwich hybrid

ization technique.
Certain factors are considered when a unique biochemical
macromolecular marker is identi?ed by means of a radio

Preferred compounds of the present invention are synthe
sized from azidoadenosine 5‘-triphosphates or combinations

active photoaf?nity label, as is the preferred method of the
present invention. For example, consideration should be
given to: (a) temperature of incubation and photolysis, (b)

thereof, which provide a (2'—5‘)oligomer containing both

adenylyl and azidoadenylyl moieties. Especially preferred

length of incubation and photolysis, (c) concentration of

photoat?nity compounds for use in the present invention
include in particular 2-azido-ATP, 8-azido-ATP and ben
zophenone-ATP or other compounds which effectively com

photoaf?nity reagent, (d) binding a?inity of protein for the
reagent and natural ligands, (e) stability of the photoa?inity
reagent in each particular system, (i) ionic strength, pH,
cofactors, (g) protein concentration, (h) intensity of photo
lyzing light, (i) quenching of reaction and separation of

pete with 2 or 8-azido-ATP for occupancy of the PRB

binding domain.
As noted, these photoaf?nity compounds may ?rrther be

unused label, and (1') interpretation of results. Potter & Haley
in Meth. in EnzymoL, 91:613-633 (1983) provide a detailed
account of preferred procedures for labeling a speci?c

attached to other molecules, e.g., effector molecules or

reporter molecules, provided that such molecules do not
adversely alfect the ability of the photoa?inity compound to
effectively photoinsert into nucleotide binding site or sites
contained in the particular antibody, or provided that such
molecules may be effectively attached to a nucleotide or

biochemical marker macromolecule in a sample with a

photosensitive purine triphosphate azide analog.
20

nucleoside photoaf?nity compound which has been bound to

from 0° C. to room temperature (25° C.) or above. However,
the exchange rate between bound and unbound cAMP or

the particular antibody.
Nonradioactive reporter molecules or labels can be

divided into two categories: (i) chromogenic, ?uorogenic, or
chemiluminescent dyes or (ii) ligands. Dyes are normally of

Temperature of the photolysis reaction between the anti
body sample and the selected photoaflinity label can range

8-N3cAMP approaches negligible levels at 0° C., and is
25

greatly increased at room temperature. Conversely, once

8-N3cAMP is bound to the speci?c macromolecular marker,
it may be cold trapped onto the protein by dropping the
temperature to nearly 0° C. Therefore, the most preferred

from 8 to 40 carbon atoms, preferably from 9 to 30 carbon
atoms. The dyes further normally contain from 1 to 10
heteroatoms usually oxygen, nitrogen, or sulfur, and nor

procedure includes preincubation of the components at room

mally contain no halogen atoms or up to 10 halogen atoms 30 temperature, and photolysis in plates set on ice to reduce the

usually iodine, bromine, chlorine, or ?uorine.

temperature to approximately 0° to 4° C. By the present

Chromogenic dyes may include phenol sulfonephthalein

invention, the antibody containing sample is preferably

and analogs of tetrazolium.

incubated at room temperature with the radioactive photo

Fluorogenic dyes may include ?uorescein isothiocyanate,

dichlorotriazinylarnino ?uorescein, morpholinorhodarnine

35

isothiocyanate, tetramethylrhodarnine isothiocyanate, and
4-acetarnido-4-isothiocyanostilbene-2 with 2'-disulfonic

a?inity probe for approximately 0.5 to 1.0 minutes. Most
preferably the mixture is vortexed for 6 seconds followed by
an additional 24 seconds of mixing, immediately followed

by placing the sample on ice for photoactivation.

acid. Fluorescent purine derivatives may also include, for

The concentration of photoaf?nity reagent must be com

example, the ?uorescent GTP analog 2'3'-O-(2,4,6-trinitro
GTP), or the equivalent ?uorescent ATP derivative TNP

patible with the binding a?inity of the antibody which is to
be labeled. Excessively high concentrations, however, can
lead to undesirable nonspeci?c labeling which increases

ATP).

linearly with concentration. Best results can be obtained by

cyclohexadienyl-idine)guanosine 5'-triphosphate (TNP
Chemiluminescent dyes may include 5-amino-2,3-dihy
dro-phthalazine-l,4-dione (luminol), derivatives of isolurni
nol and acridinium esters.

experimentally determining the optimum concentration for
45

Any ligand may be employed for which an appropriate
receptor may be found to have satisfactory speci?city for the

photoincorporation. Directly related to the determination of
concentration is the stability of the reagent. The stability of
the reagent can be determined by thin-layer chromatogra
phy, e.g., by ?uorescent cellulose thin-layer chromatogra

phy.

ligand. For example, the subject labeling method provides
for the efficient attachment of biotin to antibodies using the

Ionic strength, pH, cofactor, and metal ion concentrations

subject nucleotide or nucleoside photoa?inity compounds.
Speci?cally, this has been demonstrated by Western Blot
(testing for reaction with avidin) using azido-ATP and
azido-GTP compounds.

can each a?fect antibody structure, and are readily adjusted
by those skilled in the art to achieve optimal labeling

Various methods or protocols may be employed in mea
suring the amount of the labels. These protocols can include

conditions. The higher the protein content of the sample, the
denser the solution becomes to light. Therefore, in a denser
55

of the protein can also affect the binding time of the reagent

for example, radioimmunoassay (RIA), immunoradiometric
assay (IRMA), sandwich IRMA, ?uoroirnrnunoassay (FIA),
chemiluminescent assays, bioluminescent assays, and
enzyme linked immunosorbent assays (ELISA) among oth

60

ers.

to the protein, thereby increasing or decreasing photoincor
poration. One must experimentally redeterrnine optimal
photolysis time when changing protein concentration if
maximum incorporation of the photolabel is desired.
Detection of the labeled antibody occurs following an
appropriate, predetermined incubation time to effect a reac

The labeled probe of the present invention can be used in

any conventional hybridization technique. Hybridization
formats which may be useful in the practice of the present
invention include those in which the sample is immobilized
on a solid support (solid-phase hybridization) and those
wherein the species are all in solution (solution hybridiza

solution, less UV light reaches the photoreagent per unit of
time, decreasing the rate of photoincorporation. Aggregation

tion, and is calculated on the basis of the antibody sample
65

and the selected photoa?inity probe.
The intensity of the photolyzing light is such that maxi
mum photoincorporation can be obtained in a minimum

5,596,081
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amount of time without appreciable change in temperature
or damage to the biological sample. Preferably the photoly

phosphotransfer from the tn'phosphate derivative N3ATP or

sis is achieved at 254 nm with an ultraviolet light source.

preferred protein solubilizing agent is a detergent, particu
larly SDS, most preferably in a protein solubilizing mix

N3GTP may be inhibited by chelators such as EDTA. The

Ultraviolet (UV) light is essential for the activation of the
photoprobe treated samples, but only a low intensity UV
light is necessary. The intensity of the UV light can range
from 180 to 800 pW/cmZ by conventional sources to 4000

(PSM), such as described by Potter & Haley in Math. in

EnzymoL, 91:613-633 (1983) or by procedures standard to
most published procedures. A particularly preferred concen

achieve rapid photolysis.

tration of SDS in the mix is 10%, resulting in a concentration
of SDS to the ?nal sample of 4%.

Photolysis times range from 15 seconds to 5 minutes and
must be experimentally determined for each reaction sys

temperatures without affecting the results. However, solu

pW/cm2 and above when a high intensity source is used to

Solubilization can occur either at 0° C. or at higher

tem. For lamps having intensities of 180-800 pW/cm2, the
preferred photolysis time ranges from approximately 30 to
120 seconds, most preferably, photolysis is effected in

bilization in the present invention is effective at room

temperature.
Upon Solubilization, the protein sample is applied to a
suitable support for separation of the protein fractions.
Support materials could include, e.g., polyacrylamide gels,

approximately 30 to 60 seconds.
The distance of the light source from the sample is a
determinative factor in the conditions of photolysis. A pre

?lter paper, starch gels or blocks, cellulose or polyurethane '

ferred method of the present invention uses an ultraviolet

foam. Any effective, known method of protein separation
may be used, but preferably separation is by electrophoresis

light source having suf?cient intensity, about 6200 pW/cm2,
positioned at a set distance, about 1 cm from the sample, for
a time suf?cient to e?’ect photoactivation, generally approxi

over denaturing or nondenaturing gels, or over a gradient of

either type. In the present method, protein separation is
usually by electrophoresis on a denaturing gel.

mately 45 seconds.
The labeled macromolecule is typically separated from

The nature of the sample and the size of the speci?c

the solution containing excess unbound sample and/or label

by precipitation, although other recognized methods of
protein puri?cation are possible. Recognized methods of

25

precipitation include, but are not limited to addition of an

elfective protein precipitating agent, such as trichloroacetic

acid (TCA), perchloric acid (PCA), acetone, armnonium
sulfate polyethylene-glycol (PEG) or the like to the sample.
PCA or ammonium sulfate are the preferred precipitating

or by isoelectric focusing (IEF) or on two dimensional

agents in the present method, and PCA is the particularly

systems (IEFxSDS-PAGE). Typically, the sample is frac

preferred precipitating agent.
The amount of precipitating agent is determined by the
concentration of protein in the sample. The preferred con
centration of the precipitating agent is that concentration

nucleotide binding protein determine the concentration of
the gel used, which in tum determines the time for separa
tion and the electrical current which must be applied to best
achieve protein separation. The protein fractions of the
present invention most preferably may be separated by
electrophoresis on an SDS-polyacrylamide gel (SDS-PAGE)
tionated on a 10% polyacrylamide gel, run over a period of
21/2 to 3 hours, with constant amperage of 35 mA and an

35

which effectively precipitates the speci?c antibody from
solution. The most preferred concentration of the precipi
tating agent is that amount which effectively precipitates the

initial voltage of about 140 volts. Any standard electro
phoresis equipment can be utilized.
The resultant gels are exposed to X-ray ?lm and visual
ized by autoradiography according to methods well known
in the art. The gels can also be stained to determine the

previously activated, photolabeled antibody sample.

presence of the unique speci?c protein band or to ascertain
that differences in the amount of photolabel incorporation
are not due to drastic changes in the protein levels. Many

The precipitating agent can be mixed with the sample as
a dry batch addition or in a calculated equivalent liquid
form. The required mixing time may vary with the nature of
the agent selected and the size or concentration of the

known protein staining methods are widely recognized, e.g.,
Coomassie Brilliant Blue (CBB) or silver staining. CBB is

sample. However, the time required is that point after which
essentially no additional protein is precipitated from the
sample solution at the temperature selected.
The precipitated antibodies may be separated from solu

hydrophobic interaction between the proteins and the dye.
Although any available staining method can be used which
eifectively distinguishes the speci?c nucleotide binding pro

tion by any effective means, such as centrifugation, sedi
mentation or ?ltration. A preferred method of separation of

tein, CBB is the fastest and most economical for the present
method.

the precipitated protein from the solution is by centrifuga

a commonly used stain that detects proteins based on a

50

tion at a su?icient speed and for a su?icient time to effec

tively isolate the antibody proteins into a pellet, for example
by centrifugation. However, the parameters vary with the
nature of the antibody solution.
To determine the effectiveness of the precipitation and

protein fragments. However, many times proteins can be
detected by photolabelling that cannot be detected by any
55

protein staining procedure. In particular, the completed gel

60

is immersed in a 10% CBB (w/v) solution for about 1 hour.
Then the gel is destained in a solution to elfectively remove
excess stain. Particularly preferred is a destaining solution of
5% acetic acid and 10% isopropyl alcohol applied for 10-18
hours.

separation procedures, both the pellet and the supernatant
?uid are analyzed for protein content.
The precipitated protein may be solubilized and any

remaining reaction quenched by any effective, lmown
method. The determination of the solubilizing agent would
depend on the ultimate method of identifying the speci?c
nucleotide binding protein. Therefore, such agents could

Finally, the speci?c binding protein fragments may be
visualized by standard autoradiography techniques. The use

include, e.g., sodium dodecyl sulfate (SDS) or urea, and

certain stabilizing agents.
Any azide remaining after photolysis may be destroyed by
the addition of dithiothreitol or its equivalent, and potential

Most preferably, each completed SDS-PAGE gel is
stained with an effective amount of CBB to stain the selected

65

of an intensifying screen effectively accelerates the visual
ization process of autoradiography. By the method of the
present invention, the stained gel is dried, and then exposed
to DuPont CRONEX 4 X-ray ?lm. The autoradiographic
procedure is for variable time periods depending on the

5,596,081
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speci?c activity of the probe photoinserted into the proteins

erate, aldehydes such as glutaraldehyde, bis-azido com

of each experimental sample. Altemately, if maintained at
—70° C., the gel can be subjected to autoradiographic
procedures While still in the gel state.

pounds, bis-diazonium derivatives such as bis-(p-diazonium
benzoyl)-ethylenediamine, diisocynates such as tolylene
2,6-diisocyanate, and bis-active ?uorine compounds such as

l,5-di?uoro-2,4-ditrobenzene.

The amount of protein, as well as the radioactivity incor

porated into each protein, can be quanti?ed by known

Particular types of effector molecules considered to have

methods including, but not limited to, densitometric scans of

preferred application in the invention include radiolabels

and chelating agents, in particular triphosphate chelated

the exposed X-ray ?lm, or of the stained gel, or by liquid
scintillation spectrometry of the protein band following
excision from the gel.
As discussed supra, another application of the subject
affinity labeling method comprises the attachment of desired

heavy metals such as 111In + (which has known application

as a diagnostic imaging agent), nucleic acids having utility
in gene therapy or antisense therapy, enzymes having diag
nostic or therapeutic utility, and toxins.
Effector molecules may be attached to the photoaf?nity

effector molecules to antibodies, wherein these molecules
are site-speci?cally attached to a photoaf?nity site, in par
ticular at a site or sites having high a?inity for purine,

compound and more preferably an ATP‘ or GTP-analog

azidopurine and other similar heterocyclic bases, and more

photoa?inity compound, by various means of attachment.

particularly ATP- or GTP-analog photoaf?nity compounds.
This is an important application of the subject method given
that the present method of attachment is site-speci?c and
does not substantially affect the architecture of the antibody

The selection of suitable means of attachment will depend
upon the particular effector and functional groups available
for covalent attachment or complexation to the particular
nucleotide or nucleoside photoaftinity compound. Prefer

compound, preferably a purine or azidopurine photoa?inity

20

molecule or its ability to bind antigen. Therefore, effector

ably, such chemical attachment will occur under mild con

molecule containing antibodies produced by this method

ditions to preserve the activity of the antibody and effector.
For example, proteins may be attached to the subject

will bind to a target more effectively, e.g., a tumor cell

purine or purine derivative containing photoaf?nity probes,

expressing the corresponding antigen. Moreover, non-spe
ci?c binding should be minimized which is highly signi?

25

cant if the antibody-effector conjugate is to be used as a

therapeutic agent, since this should minimize systemic tox

icity.

hyde will then form a Schiff’s base with amino groups of

proteins or other amino group containing compounds.
Also, the subject photolabeled antibodies have been
shown to have very high a?'mity to polylysine because of the
presence of a highly negatively charged triphosphate or

The subject method is applicable for site-speci?cally
attaching any effector molecule which, when attached to a

nucleotide photoa?inity compound does not adversely affect
the ability of the resultant elfector-nucleotide photoaf?nity
compound to site-speci?cally attach to a nucleic acid bind
ing site comprised on the antibody molecule, or which may
be site-speci?cally attached to a nucleotide photoaftinity

tetraphosphate. Consequently, this will permit established
35

compound which has been previously been site-speci?cally
bound to a nucleic acid binding site on an antibody.

As noted previously, an effector molecule is broadly
de?ned as any moiety which comprises a desired functions,
e.g., a particular biological or chemical activity. In the
preferred embodiment, the effector will comprise an activity
which enables the effector-antibody conjugate to be used as
a therapeutic or an imaging agent, e.g., for treating or
visualizing tumors.
Examples of effector molecules within the scope of the

and more particularly ATP- and GTP-analog photoa?inity
compounds, by converting the cis-hydroyl group on the
ribose under gentle conditions to a dialdehyde. The dialde

procedures to be used to couple a polylysine containing
polynucleotide, e.g., DNA, RNA or complexes thereof, to
the photolabeled antibody. This will further enable the
polynucleotide to be site-speci?cally targeted to an antigen
expressing target, e.g., a tumor cell or a site of infection.
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Additionally, it has been shown that the subject nucleotide
photoa?inity compounds attach under gentle conditions to
heavy metals, e.g., triphosphate chelated metals, in particu
lar 111Ina", wherein this reaction may be effected before or

after the photoa?inity compound is attached to the antibody.

Preferably, the photoa?inity compounds will comprise ATP

invention include by way of example cytotoxic moieties

or GTP-analog photoa?inity compounds, and most prefer
ably 2-azido-ATP, 8-azido-ATP or benzophenone-ATP.

such as enzymatically active toxins and fragments thereof
such as diphtheria toxin, Pseudomonas exotoxin, ricin A,

When used in vivo for therapy, the effector-antibody con
jugates of the invention will be administered in therapeuti

abrin A, modeccin A, alpha-sarcin, Alevritesfordii proteins,
dianthin proteins, Phytolacca americana proteins (PAPI,
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PAPH, PAPIH), Momardica charantia inhibitor, carcin, ero

tin, Sapanaria o?’icinalis inhibitor, gelonin, rnitogellin,
restrictocin, phenomycin, and enomycin, antitumor agents
such as daunomycin, daunorubicin, methotrexate, cytokines
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such as interleukins (IL-1, IL-2, etc.), interferons (ot inter

cally effective amounts. This will of course depend upon

factors including the speci?c disease condition being
treated, the condition of the patient, the antigen binding
properties of the antibody (a?inity, avidity of antibody for
antigen), and the particular effector molecule that is attached
to the antibody. Particular disease conditions contemplated
for treatment include, e.g., cancers, infectious diseases, and

genetic disorders.

feron, [3 interferon, 'y interferon), colony stimulating factors,
tumor necrosis factors, and lymphotoxins, enzymes, radio

The subject photoa?inity compound antibody-conjugates

nuclides, chelating agents, growth factors, polynucleotides

will normally be administered parenterally, when possible at

(DNA, RNA, antisense DNA or RNA mixtures thereof)
heavy metal isotopes, as well as other moieties having

60 the target, e.g., a tumor, a particular organ, or a site of

infection.

therapeutic or diagnostic utility.

For parenteral administration these conjugates will be
formulated in a unit dosage injectable form (solution, sus
pension, emulsion) in association with a pharmaceutically

The effector moieties may be directly attached to the
photoa?inity compound, or attachment may be effected

using a bifunctional coupling agent. Examples of such
reagents include by way of example SPDP, IT, dimethyl
adipirnidate HCl, active esters such as disuccinimidyl sub
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acceptable parenteral vehicle. Such vehicles are inherently
nontoxic, and non-therapeutic. Examples of such vehicles
are water, saline, Ringer’s solution, dextrose solution, and
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5% human serum albumin. Nonaqueous vehicles such as

The SIC5 antibody was again labeled, but in this example
labeling was performed in the presence of increasing
amounts of free ATP. Speci?cally, 3 pg of the SIC5 antibody
was photolyzed in the presence of 200 pm [7”P1-8-N3 ATP
using concentrations of ATP ranging from O to 700 pm. The

?xed oils and ethyl oleate may also be used. Liposomes may
be used as carriers. The vehicle may contain minor amounts
of additives such as substances that enhance isotonicity and

chemical stability, e.g., buffers and preservatives. The anti

labeled protein was again separated by SDS-PAGE; and
radioactivity determined by liquid scintillation counting.

body conjugates will typically be formulated in such
vehicles at concentrations of about 1 mg/ml to 10 mg/ml.
The selection of an antibody subclass for therapy will
depend upon the nature of the antigen. For example, an IgM
may be preferred in situations where the antigen is highly
speci?c for the target and rarely occurs on normal cells.
However, where the antigen is also expressed in non

These results are shown in FIG. 2.

antibody chains of the SIC5 antibody. The results further
indicate that 50% of inhibition of labeling occurs at around
a 350 pm ATP concentration. Thus, these results provide
further evidence that the SIC5 antibody comprises one or

targeted, e.g., normal tissues, an IgG antibody may be
preferred.

'

Based on the results contained therein, it can be clearly
seen that ATP inhibits labeling of both the heavy and light

_

The following examples are offered to more further
illustrate the nature, but are not to be construed as limiting
hte scope thereof.

more sites having speci?c a?inity for the [yszPl-ii-N3 ATP

EXAMPLES

Labeling of the SIC5 Antibody Using [y3ZP]-8-N3

compound.
Example 3
ATP Benzophenone

Standard procedures and reagents were used in accor

dance with Maniatis et al (1982) Molecular Cloning: A

Another photoactivating probe, [y3ZP]-8-N3 ATP ben

Laboratory Manual, Cold Spring Harbor Laboratory, New
York. Speci?c techniques for the photoa?inity labeling of
speci?c nucleotide binding sites with purine phosphate azide
analogues were used in accordance with Potter & Haley,
Meth. in EnzymoL, 90:613-633 (1983).

zophenone, was tested to determine its ef?cacy for labeling
the SIC5 antibody. This experiment was conducted under
substantially the same conditions as Example 1, except that

[\(32P]-8-N3 benzophenone was substituted for [y32P]-8-N3.
Incorporation of label into the SIC5 heavy and light chains
were then measured. It was demonstrated that saturation was

Example 1

3O

achieved at about 100 mM concentration of probe.

These results indicate that the SIC5 antibody comprises
one or more af?nity sites which are effectively labeled by the

Labeling Efficiency of [y32P]-8-N3 ATP for SIC5

[y32P]-8-N3 ATP benzophenone compound, and that the

Antibody
The SIC5 antibody comprises an anti-B cell lymphoma
idiotype antibody which is useful for evaluating the effi
ciency of labeling by idiotype solid phase assays and tumor

SIC5 antibody may be effectively labeled using different
35

Example 4

cell binding as well as in tumor imaging. Therefore, given
these inherent properties, this antibody was selected to

Ai?nity of SIC5 Antibody Site for Oligonucleotides

determine labeling efficiency of the subject method.
In particular, 3 pg of SIC5 antibody in 30 mL of pho
tolysis buffer was photolyzed with increasing concentrations
of [y32P]-8-N3 ATP and then separated by SDS-PAGE. 32F
incorporation was detected by autoradiography and quanti
?ed by scanning on Optical Imaging Acquisition Analysis
(Ambis, Inc.). Photoincorporation was quantitatively con
?nned by cutting the appropriate bond and determining
radioactivity by liquid scintillation counting. These results
are set forth in FIG. 1. Based upon these results, it can be

clearly seen that the radioactive probe is covalently attach
ing to both antibody heavy and light chains. It can further be

The a?inity of the SIC5 antibody for oligonucleotides was
also evaluated using oligonucleotides of different length, to
block photolabeling with an ATP probe. Speci?cally, 3 pg of
the SIC5 antibody was incubated for two hours at 4° C. with

1 mg of a 24-mer, 30-mer, 33-mer, 58-mer, followed by
incubation with 200 pm of ['f""P]-8-N3 ATP for 60 seconds,

photolysis for 60 seconds, followed by separation of protein
using SDS-PAGE. Photoincorporation was again quantita
tively determined by cutting the appropriate band and deter

mining 32P radioactivity by liquid scintillation counting.
50 These results are contained in FIG. 3. Based on these results,

it would appear that blocking efficiency increases with the
length of the oligonucleotide. This provides further evidence

seen that there is a de?ned saturating concentration of probe
at about 200 tun for both chains. This saturation plateau

provides strong evidence that there exists a unique and
limited number of a?inity sites of the antibody which are

in support of the existence of one or more sites on the

antibody having speci?c affinity for ATP photoai?nity
55

bound by the [7”P1-8-N3 ATP compound.

nucleotides of speci?c sequences to further analyze the

Example 5
60

Determination of the Speci?city of the Antibody
Nucleic A?inity Site

ducted.

probes. Additional experiments are planned using oligo
sequence speci?city of the affinity site(s).

Example 2

In order to identify which part of the ['y32P]-8-N3 ATP
probe is binding the antibody, i.e., the speci?city of the
antibody a?inity site, the following experiment was con

nucleotide photoactivating probes.

Effect of Labeling on Antigen Binding
The effect of labeling on antigen binding and antigen
speci?city was determined using the 31-11 anti-idiotype anti
body, for which an idiotype is readily available. The binding

65

of 3H1 to idiotype was tested in a solid phase binding assay

(ELISA) using isotope labeled 3H1 in the presence of
unlabeled 3H1 antibody to inhibit binding.
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In particular, the idiotype antibody was used as antigen for
plate coating (500 mg/well). The same amount of labeled

IgM (lane 9), murine monoclonal lgG2b, SIC5 (lane 10)]
was photolyzed in the presence of 200 um ['f‘ZPQ-S-N3 ATP

and separated by 8-16% gradient SDS-PAGE. Following

3H1 (3 pg) was mixed with different amounts of the unla
beled antibody and incubated for two hours at 25° C. After
incubation, the wells were washed, dried, out and 32F

electrophoresis, the gel was stained with Coomassie Blue,
dried and autoradiographed. These results are contained in
FIG. 7.
The results indicate that these different antibodies effec

radioactively counted by liquid scintillation. The 5D10
antibody was used as the non-speci?c cell inhibitor.

tively incorporate the label into the heavy and light chains

These results, using different speci?c amounts of unla

and that the amount of incorporation varies with the different
antibodies. It can further be seen that a Fab fragment (goat

beled antibody ranging from 0 to 10 pg are shown in FIG.
4. It can be dearly seen from these results that the cold

Ig is Fab fragment is eifective labeled.
Thus, these results indicate that nucleotide a?inity bind
ing sites suitable for photoaf?nity nucleotide labeling are
comprised on antibodies of different species, origin and an
antibody of diiferent isotype. Moreover, these results indi

(unlabeled) 3Hl antibody inhibits the binding of isotope
labeled 3H1.

Example 6

cate that antibody fragments, as well as intact antibodies

Cell-Surface Competition Binding of Labeled SD10

may be effectively labeled using nucleotide photoaf?nity

Antibody

probes.
While the invention has been described in the terms of

The binding of isotope labeled anti-B cell lymphoma
idiotypic antibody to live tumor cells was tested. Speci?
cally, 106 SU-DPHs-4 cells were incubated with di?erent

20

amounts of unlabeled antibody and the same amount of

labeled antibody (3 mg/tube) for 30 minutes at 4° C. Cells
were then washed using 20% fetal calf serum (FCS)

medium). Binding of Y'QP-labeled antibody was detected by
liquid scintillation counting.

25

These results are contained in FIG. 5. It can be clearly

seen that the unlabeled antibody e?ectively inhibits binding
of the isotope labeled antibody to tumor cells.

various preferred embodiments, the skilled artisan will
appreciate that various modi?cations, substitutions, omis
sions, and changes may be made without departing from the
spirit thereof. Accordingly, it is intended that the scope of the
present invention be limited solely by the scope of the

following claims, including equivalents thereof.
What is claimed is:
1. A method for site speci?c photoattachment of a nucle
otide photoaf?nity compound to antibody molecules com~

prising reacting an antibody containing sample with an
30

Example 7

effective amount of a nucleotide photoa?inity compound
under ultraviolet light conditions which provide for the

site-speci?c photoinsertion of said nucleotide photoa?inity
compound at one or more nucleotide binding sites in the

Characterization of Labeled Antibodies by
lsoelectn'c Focussing

antibody molecules which are contained in the sample.
2. The method of claim 1 wherein said nucleotide pho

Labeled antibodies were also characterized by isoelectric 35 toa?inity compound is an adenosine triphosphate (ATP)

analog or a guanosine triphosphate (GTP) -analog photoaf

focusing. A representative isoelectric focusing pattern of a
labeled and unlabeled antibody is found in FIG. 6.

?nity compound.

3. The method of claim 1 wherein the nucleotide photo
Isoelectric focusing was effected at a pH ranging from 3
a?‘inity compound site-speci?cally attaches to one or more
to 10 using SIC5 antibodies which had been photolabeled 40 sites having high a?inity for purine, azidopurine or hetero
with increasing concentrations of [y32P]-8-N3 ATP. The
cyclic bases having a similar structure to purine.
isoelectric focusing standards used were:
4. The method of claim 2 wherein the ATP-analog is

A=cytochrome C (pI 9.6),

selected from the group consisting of 2-azido-ATP, 8-azido~

Bzequine myoglobin (pl 7.0),

ATP and benzophenone-ATP.

C=bovine carbonic anhydrase (pI 6.0),
D=phycocyanin (pl 4.65) (lane 10).

45

selected from the group consisting of polyclonal antibodies,
monoclonal antibodies, recombinant antibodies, chimeric

The unlabeled antibody is shown in lane 1.

SIC5 antibody (5 pg) was photolyzed by 3.125 pm (lane
9), 6.25 pm (lane 8), 12.5 pm (lane 7), 25 pm (lane 6), 50 pm
(lane 5), 100 pm (lane 4), 200 pm (lane 3), and 400 um (lane

antibodies, bispeci?c antibodies and antigen binding frag
ments.
50

6. The method of claim 1 wherein the nucleotide photo
a?inity compound is covalently bound or complexed to a
reporter molecule.
7. The method of claim 6 wherein the reporter is selected
from the group consisting of radiolabels, enzymes, chro

55

mophores, polynucleotides, and ?uorophores.

2) [y3zP]-8-Ns ATP.
Example 8
Labeling of Antibodies of Different Species and

8. The method of claim 7 wherein the reporter molecule

Isotype Using [7“P]-8-N3 ATP

is a radiolabel.

In this experiment, antibodies of diiferent species, origin
and isotype were labeled with [Y32P]-8-N3 ATP. Speci?cally,
murine, goat, human and rabbit antibodies were labeled with 60

[y32P]-8-N3 ATP. Labeling was again effected substantially
in accordance with Example 1. The same amount (3 pg) of

the respective antibodies [murine monoclonal lgGl, 5D 10

(lane 1), murine myeloma IgGl (lane 2), murine myeloma
IgA (lane 3), goat Ig (lane 4), goat (Fab)2 fragments (lane 5),
human myeloma IgGl K (lane 6), human myeloma IgGl 1
(lane 7), human myeloma IgM (lane 8), murine monoclonal

.

5. The method of claim 1 wherein said antibody is
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9. The method of claim 1 wherein the nucleotide photo
a?inity compound is covalently bound or complexed with a
molecule selected from the group consisting of proteins,
DNA, RNA, DNA or RNA containing complexes, chelating
agents, and radiolabels.
10. The method of claim 1 wherein the nucleotide pho
toa?inity compound is covalently bound to or complexed
with a heavy metal.
11. The method of claim 10 wherein said heavy metal is
radioactive.
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12. The method of claim 10 wherein the heavy metal is
iron or mercury.

13. The method of claim 11 wherein the radioactive heavy
metal is 111In“.
14. The method of claim 1 which further includes recov

16. The method of claim 1, wherein said nucleotide
photoa?inity compound is a heterocyclic base having a
purine ring which is capable of competing with an ATP or
GTP analog photoa?inity compound for an ATP or GTP

ery of the nucleotide photoa?inity compound-antibody con

binding site on the antibody molecules contained in the’

jugates by fractionation.

sample.

15. The method of claim 14 wherein the nucleotide

photoaf?nity compound-antibody conjugates are separated
from the sample by gel electrophoresis.

